Alumis’s genomic research guided its development of envudeucitinib, a TYK2 inhibitor that some analysts now view as best in class. The Phase 3 results that will support a planned FDA submission in plaque psoriasis are scheduled for presentation this weekend during the American Academy of Dermatology annual meeting in Denver.
The post Taking a Page From Cancer Drugs, Autoimmune Biotech Alumis Aims for Precision Immunology appeared first on MedCity News.
